Download MendeleyArylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
Shi, Y., O'Connor, S.P., Sitkoff, D., Zhang, J., Shi, M., Bisaha, S.N., Wang, Y., Li, C., Ruan, Z., Michael Lawrence, R., Klei, H.E., Kish, K., Liu, E.C., Seiler, S.M., Schweizer, L., Steinbacher, T.E., Schumacher, W.A., Robl, J.A., Macor, J.E., Atwal, K.S., Stein, P.D.(2011) Bioorg Med Chem Lett 21: 7516-7521
- PubMed: 22041058 Search on PubMed
- DOI: https://doi.org/10.1016/j.bmcl.2011.06.098
- Primary Citation Related Structures:
3SW2 - PubMed Abstract:
The design, synthesis and SAR of a novel class of valerolactam-based arylsulfonamides as potent and selective FXa inhibitors is reported. The arylsulfonamide-valerolactam scaffold was derived based on the proposed bioisosterism to the arylcyanoguanidine-caprolactam core in known FXa inhibitors. The SAR study led to compound 46 as the most potent FXa inhibitor in this series, with an IC(50) of 7 nM and EC(2×PT) of 1.7 μM. The X-ray structure of compound 40 bound to FXa shows that the sulfonamide-valerolactam scaffold anchors the aryl group in the S1 and the novel acylcytisine pharmacophore in the S4 pockets.
- Research and Development, Bristol-Myers Squibb Company, PO Box 5400, Princeton, NJ 08543-5400, USA. Michael
Organizational Affiliation:
